Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Dexamethasone
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
PIF Partners Granted FDA Rare Pediatric Disease Designation for Small Molecule
Details : ‘005 (101-PGC-005) is a Type IA prodrug of dexamethasone that targets CD206+ macrophages. It is being evaluated for the treatment of systemic juvenile idiopathic arthritis.
Product Name : 101-PGC-005
Product Type : Steroid
Upfront Cash : Inapplicable
December 03, 2024
Lead Product(s) : Dexamethasone
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable